Actavis’s new drug Avycaz (ceftazidime + avibactam) got USFDA approval
The U.S. Food and Drug Administration on Wednesday approved the use of Actavis Plc’s antibiotic, Avycaz, to battle drug-resistant bacteria known as... Read More
Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo®
Posted on26 Feb 2015
TagsEdition Clinical Trial, Lantus, Sanofi, Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo®, Toujeo
Comments0
Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily... Read More
FDA approves Farydak for treatment of multiple myeloma
The U.S. Food and Drug Administration today approved Farydak (panobinostat) for the treatment of patients with multiple myeloma. Overview of Multiple Myeloma... Read More
Launch of Turing Pharmaceuticals – New Drug Company
Turing Pharmaceuticals AG announced its official launch today, along with news of three acquisitions for its commercial operations and development pipeline. The... Read More
Shire is to acquire Meritage Pharma
Posted on25 Feb 2015
Comments0
Acquiring Company: Shire plc Company to acquire: Meritage Pharma Why is Shire acquiring Meritage Pharma? Shire is to acquire San Diego-based Meritage Pharma... Read More
Elder Pharma’s entry into nasal decongestant market
Expanding its over-the-counter (OTC) products range, Elder Pharmaceuticals Limited has launched Solo range of inhalers for nasal congestion. The Solo basket comprises... Read More
Case Study – GSK strengthening early stage vaccine pipeline with acquisition of GlycoVaxyn AG
GSK has acquired GlycoVaxyn AG, a specialist vaccine biopharmaceutical company based in Switzerland. Since forming a scientific collaboration in 2012, GSK has... Read More
Zydus completes phase I studies of ZYAN1 for treating anaemia
Zydus Cadila, an Ahmedabad-based innovative, global pharmaceutical company, has completed the single ascending dose (SAD) range finding studies of ZYAN1 in healthy... Read More
Eisai got Approval for Antiepileptic Drug Banzel (rufinamide) As Adjunctive Treatment For Pediatric Patients
Posted on17 Feb 2015
Tagsadditional indication approval, approval of an additional pediatric indication, Eisai got Approval for Antiepileptic Drug Banzel (rufinamide) As Adjunctive Treatment For Pediatric Patients, Indication approval for, Lennox-Gastaut Syndrome, Rufinamide, Rufinamide is a triazole derivative
Comments0
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has received approval of an additional pediatric indication for Eisai’s antiepileptic... Read More
Pfenex And Hospira Collaboration To Develop And Commercialize LUCENTIS® Biosimilar
Pfenex Inc, a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., (NYSE: HSP), the world’s leading provider... Read More